Featured Research

from universities, journals, and other organizations

New skin patch treatment kills most common form of skin cancer

Date:
June 11, 2012
Source:
Society of Nuclear Medicine
Summary:
A customized patch treatment for basal cell carcinoma completely destroys facial tumors without surgery or major radiation therapy in 80 percent of patients studied, say researchers.

A customized patch treatment for basal cell carcinoma completely destroys facial tumors without surgery or major radiation therapy in 80 percent of patients studied, say researchers at the Society of Nuclear Medicine's 2012 Annual Meeting.

There are two main types of skin cancer:melanoma, which forms deep in the cells that produce pigment in skin, and nonmelanoma cancer, such as basal cell carcinoma and squamous cell carcinoma. Basal cell carcinoma is the most common type of skin cancer that affects the surface layer of the skin. Researchers have developed a treatment called a phosphorus-32 (P-32) skin patch, a radiation spot-treatment in the form of a patch that can safely and easily kill skin tumors with a few easy outpatient appointments. This therapy is ideal for patients with skin cancers that are very difficult to operate on, especially if skin grafting after surgery would be a challenge.

"The study is important for the field of nuclear medicine as it opens a new dimension in the field of therapeutic nuclear medicine and dermatology, especially for the treatment of skin malignancies," says Priyanka Gupta, Ph.D., the lead of author of the study at All India Institute of Medical Sciences, New Delhi, India. "For patients, it is beneficial because it is a simple, inexpensive and convenient procedure that does not require them to be admitted to the hospital. This may become the standard procedure for treating basal cell carcinoma or serve as an alternative when surgery and radiotherapy are not possible."

According to the World Health Organization (WHO), somewhere between two and three million nonmelanoma skin cancers develop each year around the globe, and one in every three cancers diagnosed is a skin cancer. In the United States, it is estimated that one in five Americans will develop the disease at some point in their lives.

In this study, a total of 10 patients between the ages of 32 and 74 years with facial basal cell carcinoma were treated with custom-made and fully sealed P-32 patches. Subjects had lesions near the eyes, the nose and the forehead, and all were treated locally with the P-32 patch for three hours on an outpatient basis. The custom patches were reapplied on the fourth and seventh days after the first treatment for another three hours each, delivering a fragmented dose of 100 Gy (a measurement of radiation exposure) to the cancerous lesions only -- without harming deeper structures or other areas of healthy skin on the face. Biopsies were taken at three months and repeated within the three years that followed treatment, and eight out of 10 patients were found to be entirely cured and cancer free.

Further research will need to be conducted before the P-32 patch can be provided for general clinical use to treat basal cell carcinoma and similar superficial skin cancers.


Story Source:

The above story is based on materials provided by Society of Nuclear Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society of Nuclear Medicine. "New skin patch treatment kills most common form of skin cancer." ScienceDaily. ScienceDaily, 11 June 2012. <www.sciencedaily.com/releases/2012/06/120611134045.htm>.
Society of Nuclear Medicine. (2012, June 11). New skin patch treatment kills most common form of skin cancer. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2012/06/120611134045.htm
Society of Nuclear Medicine. "New skin patch treatment kills most common form of skin cancer." ScienceDaily. www.sciencedaily.com/releases/2012/06/120611134045.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WHO Calls for Ban on E-Cigarette Sales to Minors

WHO Calls for Ban on E-Cigarette Sales to Minors

AFP (Aug. 26, 2014) The World Health Organization called Tuesday on governments should ban the sale of e-cigarettes to minors, warning that they pose a "serious threat" to foetuses and young people. Duration: 01:44 Video provided by AFP
Powered by NewsLook.com
Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Have You Ever Been 'Sleep Drunk?' 1 in 7 Has

Newsy (Aug. 26, 2014) A study published in the journal "Neurology" interviewed more than 19,000 people and found 15 percent suffer from being "sleep drunk." Video provided by Newsy
Powered by NewsLook.com
Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Does Medical Marijuana Reduce Painkiller Overdose Deaths?

Newsy (Aug. 26, 2014) A new study found fewer deaths from prescription drug overdoses in states that have legalized medical marijuana. But experts disagree on the results. Video provided by Newsy
Powered by NewsLook.com
Official: British Ebola Sufferer Receiving Experimental Drug

Official: British Ebola Sufferer Receiving Experimental Drug

AFP (Aug. 26, 2014) A British nurse infected with Ebola while working in Sierra Leone is being given the same experimental drug used on two US missionaries who have recovered for the disease, doctors in London say. Duration: 00:44 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins